- Home
- PGEN vs AVIR Comparison
PGEN vs AVIR Comparison
Compare PGEN & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PGEN | AVIR |
|---|---|---|
| Founded | 1998 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 429.1M |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PGEN | AVIR |
|---|---|---|
| Price | $7.79 | $5.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 1 |
| Target Price | $8.33 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 3.7M | 239.9K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | ★ 0.03 | N/A |
| Revenue | $230,981,000.00 | ★ $351,367,000.00 |
| Revenue This Year | $1,115.92 | N/A |
| Revenue Next Year | $81.04 | N/A |
| P/E Ratio | $256.67 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.99 | $2.78 |
| 52 Week High | $8.04 | $6.45 |
Technical Indicators
Market Signals| Indicator | PGEN | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 62.19 | 47.16 |
| Support Level | $6.57 | $5.09 |
| Resistance Level | N/A | $5.79 |
| Average True Range (ATR) | 0.38 | 0.23 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 73.12 | 23.53 |
Price Performance
Historical ComparisonAbout PGEN Precigen Inc.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.